Transcatheter heart valve implantation is a minimally-invasive heart procedure to repair damaged heart valves with bio-prosthetic valves for treatment of valvular heart disease (VHD). It is an alternative approach to conventional open heart surgery and is especially recommended for extremely high risk patients. The aortic valve is located between the left lower heart chamber (left ventricle) and the body's main artery (aorta). If the valve does not open correctly, blood flow from the heart to the body is reduced. Transcatheter aortic valve replacement (TAVR) is approved by the U.S. FDA for treating individuals suffering from symptomatic aortic stenosis and are at high risk for standard valve replacement surgery. TAVR can help restore blood flow and reduce the signs and symptoms of aortic valve stenosis - such as chest pain, shortness of breath, fainting and fatigue. TAVR may be an option for people who are at risk of complications from surgical aortic valve replacement (open-heart surgery). Increasing demand for minimally-invasive procedures is expected to boost growth of the global transcatheter heart valve market over the forecast period.
Market Dynamics
Increasing adoption of inorganic growth strategies, such as acquisitions by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in June 2020, SMT, a manufacturer of medical equipment, announced that it has acquired structural heart medical device firm Vascular Concepts, to enter into the market.
Key features of the study:
- This report provides in-depth analysis of the global transcatheter heart valve market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global transcatheter heart valve market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Edwards Lifesciences Corporation, Medtronic, Boston Scientific Corporation, Abbott, JenaValve Technology, SYMETIS, Braile Biomedica, CryoLife, Inc., Shockwave Medical Inc., Venus Medtech (Hangzhou) Inc.
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global transcatheter heart valve market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transcatheter heart valve market
Detailed Segmentation:
- Global Transcatheter Heart Valve Market, By Product Type:
- TAVR
- TMVR
- Global Transcatheter Heart Valve Market, By Delivery Systems:
- Transfemoral Approach
- Transapical Approach
- Transaortic Approach
- Global Transcatheter Heart Valve Market, By End User:
- Hospitals
- Ambulatory Surgical Centers
- Cardiac Catheterization Laboratory
- Other (Specialty Center, etc.)
- Global Transcatheter Heart Valve Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Edwards Lifesciences Corporation*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Medtronic
- Boston Scientific Corporation
- Abbott, JenaValve Technology
- SYMETIS
- Braile Biomedica
- CryoLife, Inc.
- Shockwave Medical Inc.
- Venus Medtech (Hangzhou) Inc.
"*" marked represents similar segmentation in other categories in the respective section.